Jane Street’s Sunshine Biopharma SBFM Stock Holding History

Jane Street’s Portfolio SBFM Stock Details SBFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.4K	Buy	+14,974	New	+$95.9K	﹤0.01%	11085
2024 Q3	–	Sell	-139	Closed	-$11.6K	–	10308
2024 Q2	$11.6K	Buy	139 +135	+3,375%	+$64.3K	﹤0.01%	9098
2024 Q1	$5.3K	Buy	+4	New	+$11.8K	﹤0.01%	9007
2022 Q2	–	Sell	-1	Closed	-$31K	–	10718
2022 Q1	$31K	Buy	+1	New	+$48.7K	﹤0.01%	9822

Other funds holding SBFM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SFG

Strive Financial Group Carmel, Indiana $230M AUM

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Jane Street's SBFM Position: Q2 2026 in Review

Jane Street opened a new position in Sunshine Biopharma (SBFM) in Q2 2026: 14,974 shares worth $31.4K. The stake represents ﹤0.01% of the portfolio and ranks #11085 among its holdings. This is a return to the name: Jane Street previously reported a position in SBFM as recently as Q2 2024.

Jane Street first reported a position in SBFM in Q1 2022 and has held it in 4 quarters since. 9 funds tracked by Wall St. Rank hold SBFM as of Q2 2026.

Jane Street held 14,974 shares of Sunshine Biopharma worth $31.4K as of Q2 2026.
Sunshine Biopharma was a new Jane Street position in Q2 2026.
Sunshine Biopharma made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #11085 holding.
Jane Street first reported a position in Sunshine Biopharma in Q1 2022 and has held it in 4 quarters since.
9 funds tracked by Wall St. Rank held Sunshine Biopharma as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.